Market capitalization | €83.60m |
Enterprise Value | €101.78m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 236.70 |
P/S ratio (TTM) P/S ratio | 194.42 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -48.54% |
Revenue (TTM) Revenue | €430.00k |
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
3 Analysts have issued a Sequana Medical forecast:
3 Analysts have issued a Sequana Medical forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.43 0.43 |
49%
49%
|
|
Gross Profit | -3.25 -3.25 |
26%
26%
|
|
EBITDA | -23 -23 |
24%
24%
|
EBIT (Operating Income) EBIT | -23 -23 |
24%
24%
|
Net Profit | -27 -27 |
16%
16%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company focuses on the treatment solutions for the management of liver disease, heart failure, malignant ascites, and other fluid imbalance disorders. It offers alfapump, an implantable, programmable, wirelessly-charged, battery-powered system that manages refractory ascites and malignant ascites. The company was founded by Noel L. Johnson in 2006 and is headquartered in Ghent, Belgium.
Head office | Belgium |
CEO | Ian Crosbie |
Founded | 2018 |
Website | www.sequanamedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.